Status:
TERMINATED
Treatment for Acute Spinal Cord Injury
Lead Sponsor:
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Conditions:
Spinal Cord Injury
Eligibility:
All Genders
15-60 years
Phase:
PHASE1
PHASE2
Brief Summary
This clinical trial aims to treat a damaged spinal cord by injecting your own bone marrow stromal cells (autologous bone marrow stromal cells) into cerebrospinal fluid through the lumbar puncture, and...
Eligibility Criteria
Inclusion
- Spinal cord injury is confirmed with MRI
- Methylprednisolone therapy according to this study can be started within 8 hours after the injury
- Bone marrow stromal cells (BMSCs) incubation can be started within 72 hours after the injury
- Age between 15 and 60
- With the informed consent of obtaining bone marrow and injecting incubated BMSCs.
Exclusion
- Complete disruption of spinal cord
- Central spinal cord injury
- Spinal canal stenosis before the injury
- Brain or spinal cord disease before the injury
- Positive serologic test in at least one of the following; HBs antigen, HCV antibody, HIV antibody, or HTLV-1 antibody
- Pregnancy
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00695149
Start Date
July 1 2005
End Date
March 1 2010
Last Update
June 2 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kansai Medical University
Moriguchi, Osaka, Japan, 570-8507